BAC
Bank of America Corporation
BAC's fundamentals are strong: its operating margin rose 5 points to 35% and revenue grew 15%. At 12x earnings, it's trading in line with its usual 13x. Analysts expect earnings growth.
MSTR
Strategy Inc
There isn't enough reported data to score MSTR yet.
BAC Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| N/A | |
| N/A |
BAC's revenue and profitability are currently healthy. Free cash flow and net leverage aren't meaningful measures for financial services companies like BAC.
MSTR Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Weak | |
| Under pressure | |
| Strong |
MSTR's balance sheet is currently strong, and its revenue is stable, but its profitability and cash flow are under pressure.
BAC PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 9.4x | $39.50 | -22% |
| Forward | 10x | $50.51 | — |
| Current | 12x | $50.51 | — |
| Fair | 13x | $53.81 | +6.5% |
| Expensive | 15x | $62.23 | +23% |
Historical ranges are pointers, not guarantees.
BAC's PE is in its fair range at 12x. If earnings grow as analysts expect, today's price would be 10x next year's earnings, in its cheap range.
MSTR PE Valuation
MSTR has no meaningful PE right now: it lost money over the past year.
BAC Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Growth | |
| Growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect earnings and revenue growth for BAC, with profitability improving.
MSTR Forward outlook
There aren't enough analyst estimates for MSTR to show an outlook.
BAC Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $4.92 | +17% |
| Q3 2026 | $4.19 | +14% |
| Q2 2026 | $4.34 | +27% |
| Q1 2026 | $4.02 | +20% |
| Q4 2025 | $3.81 | +19% |
| Q3 2025 | $3.66 | +33% |
| Q2 2025 | $3.41 | +20% |
| Q1 2025 | $3.35 | +16% |
| Q4 2024 | $3.21 | +4.2% |
BAC has the edge over MSTR on earnings quality, reporting a profit while its opponent remains loss making.
MSTR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$57.71 | -374% |
| Q2 2026 | -$94.04 | -960% |
| Q1 2026 | -$36.99 | -$14.75 |
| Q4 2025 | -$15.23 | -$9.17 |
| Q3 2025 | $21.07 | +$23.35 |
| Q2 2025 | $10.93 | +$12.50 |
| Q1 2025 | -$22.24 | -$21.39 |
| Q4 2024 | -$6.06 | -330% |
MSTR has swung to a loss: it lost $57.71 per share over the past year, after a profit the year before.
BAC Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $30B | +6.7% |
| Q2 2026 | $31.6B | +19% |
| Q1 2026 | $30.3B | +11% |
| Q4 2025 | $31.2B | +23% |
| Q3 2025 | $28.1B | +11% |
| Q2 2025 | $26.5B | +4.3% |
| Q1 2025 | $27.4B | +6% |
| Q4 2024 | $25.3B | +15% |
BAC has the edge over MSTR on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 30% | -3.7 points |
| Q2 2026 | 37% | +7.6 points |
| Q1 2026 | 34% | +4.7 points |
| Q4 2025 | 40% | +12 points |
| Q3 2025 | 34% | +4.8 points |
| Q2 2025 | 29% | -0.7 points |
| Q1 2025 | 30% | +1.5 points |
| Q4 2024 | 28% | +14 points |
BAC's operating margin was 30% last quarter, down 3.7 points from the same quarter a year ago.
MSTR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $125.4M | -2.5% |
| Q2 2026 | $122.4M | +6.9% |
| Q1 2026 | $124.3M | +12% |
| Q4 2025 | $123M | +1.9% |
| Q3 2025 | $128.7M | +11% |
| Q2 2025 | $114.5M | +2.7% |
| Q1 2025 | $111.1M | -3.6% |
| Q4 2024 | $120.7M | -3% |
MSTR's revenue has picked up after five years of holding roughly level: $125M last quarter, down 2.5% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 16671% | +13648 points |
| Q2 2026 | -6808% | -19064 points |
| Q1 2026 | -11642% | -6310 points |
| Q4 2025 | -14185% | -13343 points |
| Q3 2025 | 3023% | +3396 points |
| Q2 2025 | 12256% | +12436 points |
| Q1 2025 | -5331% | -5155 points |
| Q4 2024 | -842% | -808 points |
MSTR has the edge over BAC on profitability, with a higher operating margin.
BAC Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$6.5B | -114% |
| Q2 2026 | $29B | +$38.2B |
| Q1 2026 | $41.8B | +$44B |
| Q4 2025 | -$22.9B | -189% |
| Q3 2025 | $46.9B | +$84.2B |
| Q2 2025 | -$9.1B | -150% |
| Q1 2025 | -$2.2B | +$13.4B |
| Q4 2024 | $25.9B | -21% |
BAC has the edge over MSTR on cash generation, producing positive trailing cash flow while its opponent burns cash.
MSTR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $4M | +$15.1M |
| Q2 2026 | -$5.9M | +$31.1M |
| Q1 2026 | $13M | +$18.2M |
| Q4 2025 | -$22.2M | -$4.6M |
| Q3 2025 | -$11.1M | +$30.3M |
| Q2 2025 | -$37M | -$13M |
| Q1 2025 | -$5.1M | -119% |
| Q4 2024 | -$17.6M | -2204% |
MSTR has burned cash in six of the last eight quarters: −$11M over the past year, against −$71M the year before.
BAC Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -1% | -72M shares |
| 1 year | -5.3% | -405M shares |
| 3 years | -11% | -854M shares |
| 5 years | -15% | -1.3B shares |
| Available history | -24% | -2.2B shares |
BAC has the edge over MSTR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $6B |
| Q2 2026 | $6B |
| Q1 2026 | $7.2B |
| Q4 2025 | $6.3B |
| Q3 2025 | $5.3B |
| Q2 2025 | $5.3B |
| Q1 2025 | $4.5B |
| Q4 2024 | $3.5B |
BAC spent $25.6B buying back its own shares over the past year, up 37% from the year before.
MSTR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +21% | +75.5M shares |
| 1 year | +36% | +113M shares |
| 3 years | +201% | +286M shares |
| 5 years | +328% | +328M shares |
| Available history | +314% | +325M shares |
MSTR has 428M diluted shares, up 36% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2021 | — |
| Q3 2021 | — |
| Q2 2021 | — |
| Q1 2021 | — |
| Q4 2020 | $744,000 |
| Q3 2020 | $60.6M |
| Q2 2020 | $11.1M |
| Q1 2020 | $50.7M |
BAC Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 6.4x | High |
| Q2 2026 | 6.7x | High |
| Q1 2026 | 7.1x | High |
| Q4 2025 | 7.7x | High |
| Q3 2025 | 8.3x | High |
| Q2 2025 | 8.8x | High |
| Q1 2025 | 8.6x | High |
| Q4 2024 | 9.0x | High |
BAC's net debt is about 6.4 years of its operating earnings (EBITDA), down from 8.3 years a year ago. Net leverage isn't a meaningful measure for financial services companies like BAC.
MSTR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2025 | 0.7x | Very low |
| Q2 2025 | 1.2x | Healthy |
| Q3 2020 | -5.2x | Net Cash |
| Q2 2020 | -11.9x | Net Cash |
| Q1 2020 | -17.1x | Net Cash |
| Q4 2019 | -29.1x | Net Cash |
MSTR's net debt is less than a year of its operating earnings (EBITDA), after holding more cash than debt a year ago.
BAC Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 37.1 | Neutral |
| Stochastic | 4.9 | Oversold |
BAC's weekly RSI is 37 (neutral) and its Stochastic is 5 (oversold).
MSTR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 42.4 | Neutral |
| Stochastic | 42.1 | Neutral |
MSTR's weekly RSI is 42 (neutral) and its Stochastic is 42 (neutral).
BAC PE vs Financial Services Sector
| Metric | BAC | Sector median | Relative |
|---|---|---|---|
| PE | 12x | 13x | 7.5% below |
| PE % | 40 | 63 | 23 pts below |
BAC is trading at 12x earnings, in line with the Financial Services sector's median of 13x.
MSTR PE vs Technology Sector
| Metric | MSTR | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 28x | — |
MSTR has no meaningful PE right now: it lost money over the past year.
BAC Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $52.1 | 3% below |
| 20 week MA | $57.8 | 13% below |
| 50 week MA | $54.7 | 7.7% below |
| 100 week MA | $50.5 | 0% below |
| 200 week MA | $42.5 | 19% above |
BAC has the edge over MSTR on trend strength, trading above more of its moving averages.
MSTR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $141.2 | 19% below |
| 20 week MA | $123.6 | 7.4% below |
| 50 week MA | $138.1 | 17% below |
| 100 week MA | $235.9 | 52% below |
| 200 week MA | $168.2 | 32% below |
MSTR is in a downtrend: it's below all five of its weekly moving averages, and 32% below its 200-week average.
BAC Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $35.4 | $30.0 | -15% |
| 2021 | $30.0 | $44.4 | +48% |
| 2022 | $44.4 | $32.5 | -27% |
| 2023 | $32.5 | $33.7 | +3.7% |
| 2024 | $33.7 | $44.3 | +32% |
| 2025 | $44.3 | $56.2 | +27% |
| 2026 YTD | $56.2 | $50.5 | -10% |
BAC has the edge over MSTR on returns for 2026, with the stronger performance.
MSTR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $14.5 | $32.3 | +123% |
| 2021 | $32.3 | $59.7 | +85% |
| 2022 | $59.7 | $16.3 | -73% |
| 2023 | $16.3 | $63.2 | +288% |
| 2024 | $63.2 | $330.0 | +422% |
| 2025 | $330.0 | $158.8 | -52% |
| 2026 YTD | $158.8 | $114.4 | -28% |
MSTR's yearly returns have swung widely, from +422% in 2024 to −73% in 2022. It's down 28% so far in 2026.